Indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

K Tang, YH Wu, Y Song, B Yu - Journal of Hematology & Oncology, 2021 - Springer
Abstract Indoleamine 2, 3-dioxygenase 1 (IDO1) is a heme enzyme that catalyzes the
oxidation of L-tryptophan. Functionally, IDO1 has played a pivotal role in cancer immune …

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

M Platten, EAA Nollen, UF Röhrig, F Fallarino… - Nature reviews Drug …, 2019 - nature.com
Abstract l-Tryptophan (Trp) metabolism through the kynurenine pathway (KP) is involved in
the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp …

Tryptophan metabolism as a pharmacological target

M Modoux, N Rolhion, S Mani, H Sokol - Trends in pharmacological …, 2021 - cell.com
L-Tryptophan is an essential amino acid required for protein synthesis. It undergoes an
extensive and complex metabolism along several pathways, resulting in many bioactive …

Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan–kynurenine–aryl hydrocarbon axis

BW Labadie, R Bao, JJ Luke - Clinical Cancer Research, 2019 - AACR
Significant progress has been made in cancer immunotherapy with checkpoint inhibitors
targeting programmed cell death protein 1 (PD-1)–programmed death-ligand 1 signaling …

The therapeutic potential of targeting tryptophan catabolism in cancer

CA Opitz, LF Somarribas Patterson… - British journal of …, 2020 - nature.com
Based on its effects on both tumour cell intrinsic malignant properties as well as anti-tumour
immune responses, tryptophan catabolism has emerged as an important metabolic regulator …

The trans-omics landscape of COVID-19

P Wu, D Chen, W Ding, P Wu, H Hou, Y Bai… - Nature …, 2021 - nature.com
The outbreak of coronavirus disease 2019 (COVID-19) is a global health emergency.
Various omics results have been reported for COVID-19, but the molecular hallmarks of …

Immune-modulating enzyme indoleamine 2, 3-dioxygenase is effectively inhibited by targeting its apo-form

MT Nelp, PA Kates, JT Hunt, JA Newitt… - Proceedings of the …, 2018 - National Acad Sciences
For cancer cells to survive and proliferate, they must escape normal immune destruction.
One mechanism by which this is accomplished is through immune suppression effected by …

Where do recent small molecule clinical development candidates come from?

DG Brown, J Boström - Journal of medicinal chemistry, 2018 - ACS Publications
An analysis of 66 published clinical candidates from Journal of Medicinal Chemistry has
been conducted to shed light on which lead generation strategies are most frequently …

Promising nanomedicines of shikonin for cancer therapy

C Yan, Q Li, Q Sun, L Yang, X Liu, Y Zhao… - International journal …, 2023 - Taylor & Francis
Malignant tumor, the leading cause of death worldwide, poses a serious threat to human
health. For decades, natural product has been proven to be an essential source for novel …

Research progress in biological activities of succinimide derivatives

Z Zhao, J Yue, X Ji, M Nian, K Kang, H Qiao… - Bioorganic …, 2021 - Elsevier
Succinimides are well recognized heterocyclic compounds in drug discovery which produce
diverse therapeutically related applications in pharmacological practices. Researches in …